Lonza Pharma & Biotech and Innosieve Diagnostics announced today an exclusive distribution agreement for rapid bioburden testing technology. This agreement expands Lonza’s extensive offering of ...
The Global Bioburden Testing Market has experienced consistent growth, with a compound annual growth rate (CAGR) of 12-15%. This growth is driven by tightening regulatory standards and an increasing ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果